BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22152120)

  • 1. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
    Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
    BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
    Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW; Huber PE; Debus J; Bischof M
    BMC Cancer; 2014 May; 14():350. PubMed ID: 24885755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
    Issels RD; Lindner LH; Verweij J; Wust P; Reichardt P; Schem BC; Abdel-Rahman S; Daugaard S; Salat C; Wendtner CM; Vujaskovic Z; Wessalowski R; Jauch KW; Dürr HR; Ploner F; Baur-Melnyk A; Mansmann U; Hiddemann W; Blay JY; Hohenberger P; ;
    Lancet Oncol; 2010 Jun; 11(6):561-70. PubMed ID: 20434400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
    Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
    Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
    Gortzak E; Azzarelli A; Buesa J; Bramwell VH; van Coevorden F; van Geel AN; Ezzat A; Santoro A; Oosterhuis JW; van Glabbeke M; Kirkpatrick A; Verweij J;
    Eur J Cancer; 2001 Jun; 37(9):1096-103. PubMed ID: 11378339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
    Jebsen NL; Bruland ØS; Eriksson M; Engellau J; Turesson I; Folin A; Trovik CS; Hall KS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1359-66. PubMed ID: 20933339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
    Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
    Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
    J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
    Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
    Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
    BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
    J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
    Issels RD; Abdel-Rahman S; Wendtner C; Falk MH; Kurze V; Sauer H; Aydemir U; Hiddemann W
    Eur J Cancer; 2001 Sep; 37(13):1599-608. PubMed ID: 11527684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
    Spunt SL; Francotte N; De Salvo GL; Chi YY; Zanetti I; Hayes-Jordan A; Kao SC; Orbach D; Brennan B; Weiss AR; van Noesel MM; Million L; Alaggio R; Parham DM; Kelsey A; Randall RL; McCarville MB; Bisogno G; Hawkins DS; Ferrari A
    Eur J Cancer; 2019 May; 112():98-106. PubMed ID: 30954717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
    Stubbe F; Agaimy A; Ott O; Lettmaier S; Vassos N; Croner R; Hohenberger W; Fietkau R; Semrau S
    Cancer Radiother; 2016 Feb; 20(1):6-13. PubMed ID: 26700874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.